Cargando…
Suppression of Lung Adenocarcinoma Progression by Nkx2-1
Despite the high prevalence and poor outcome of patients with metastatic lung cancer, the mechanisms of tumour progression and metastasis remain largely uncharacterized. We modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS1 and inactivation of the p53-p...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088778/ https://www.ncbi.nlm.nih.gov/pubmed/21471965 http://dx.doi.org/10.1038/nature09881 |
_version_ | 1782202931442876416 |
---|---|
author | Winslow, Monte M. Dayton, Talya L. Verhaak, Roel G. W. Kim-Kiselak, Caroline Snyder, Eric L. Feldser, David M. Hubbard, Diana D. DuPage, Michel J. Whittaker, Charles A. Hoersch, Sebastian Yoon, Stephanie Crowley, Denise Bronson, Roderick T. Chiang, Derek Y. Meyerson, Matthew Jacks, Tyler |
author_facet | Winslow, Monte M. Dayton, Talya L. Verhaak, Roel G. W. Kim-Kiselak, Caroline Snyder, Eric L. Feldser, David M. Hubbard, Diana D. DuPage, Michel J. Whittaker, Charles A. Hoersch, Sebastian Yoon, Stephanie Crowley, Denise Bronson, Roderick T. Chiang, Derek Y. Meyerson, Matthew Jacks, Tyler |
author_sort | Winslow, Monte M. |
collection | PubMed |
description | Despite the high prevalence and poor outcome of patients with metastatic lung cancer, the mechanisms of tumour progression and metastasis remain largely uncharacterized. We modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS1 and inactivation of the p53-pathway2, using conditional alleles in mice3–5. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development4. Although tumours are initiated synchronously by defined genetic alterations, only a subset become malignant, suggesting that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK-2 related homeobox transcription factor Nkx2-1 (Ttf-1/Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1-negativity is pathognomonic of high-grade poorly differentiated tumours. Gain-and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1 regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically-restricted chromatin regulator Hmga2. While focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function6–9, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability, and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor. |
format | Text |
id | pubmed-3088778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
record_format | MEDLINE/PubMed |
spelling | pubmed-30887782011-11-05 Suppression of Lung Adenocarcinoma Progression by Nkx2-1 Winslow, Monte M. Dayton, Talya L. Verhaak, Roel G. W. Kim-Kiselak, Caroline Snyder, Eric L. Feldser, David M. Hubbard, Diana D. DuPage, Michel J. Whittaker, Charles A. Hoersch, Sebastian Yoon, Stephanie Crowley, Denise Bronson, Roderick T. Chiang, Derek Y. Meyerson, Matthew Jacks, Tyler Nature Article Despite the high prevalence and poor outcome of patients with metastatic lung cancer, the mechanisms of tumour progression and metastasis remain largely uncharacterized. We modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS1 and inactivation of the p53-pathway2, using conditional alleles in mice3–5. Lentiviral-mediated somatic activation of oncogenic Kras and deletion of p53 in the lung epithelial cells of Kras(LSL-G12D/+);p53(flox/flox) mice initiates lung adenocarcinoma development4. Although tumours are initiated synchronously by defined genetic alterations, only a subset become malignant, suggesting that disease progression requires additional alterations. Identification of the lentiviral integration sites allowed us to distinguish metastatic from non-metastatic tumours and determine the gene expression alterations that distinguish these tumour types. Cross-species analysis identified the NK-2 related homeobox transcription factor Nkx2-1 (Ttf-1/Titf1) as a candidate suppressor of malignant progression. In this mouse model, Nkx2-1-negativity is pathognomonic of high-grade poorly differentiated tumours. Gain-and loss-of-function experiments in cells derived from metastatic and non-metastatic tumours demonstrated that Nkx2-1 controls tumour differentiation and limits metastatic potential in vivo. Interrogation of Nkx2-1 regulated genes, analysis of tumours at defined developmental stages, and functional complementation experiments indicate that Nkx2-1 constrains tumours in part by repressing the embryonically-restricted chromatin regulator Hmga2. While focal amplification of NKX2-1 in a fraction of human lung adenocarcinomas has focused attention on its oncogenic function6–9, our data specifically link Nkx2-1 downregulation to loss of differentiation, enhanced tumour seeding ability, and increased metastatic proclivity. Thus, the oncogenic and suppressive functions of Nkx2-1 in the same tumour type substantiate its role as a dual function lineage factor. 2011-04-06 2011-05-05 /pmc/articles/PMC3088778/ /pubmed/21471965 http://dx.doi.org/10.1038/nature09881 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Winslow, Monte M. Dayton, Talya L. Verhaak, Roel G. W. Kim-Kiselak, Caroline Snyder, Eric L. Feldser, David M. Hubbard, Diana D. DuPage, Michel J. Whittaker, Charles A. Hoersch, Sebastian Yoon, Stephanie Crowley, Denise Bronson, Roderick T. Chiang, Derek Y. Meyerson, Matthew Jacks, Tyler Suppression of Lung Adenocarcinoma Progression by Nkx2-1 |
title | Suppression of Lung Adenocarcinoma Progression by Nkx2-1 |
title_full | Suppression of Lung Adenocarcinoma Progression by Nkx2-1 |
title_fullStr | Suppression of Lung Adenocarcinoma Progression by Nkx2-1 |
title_full_unstemmed | Suppression of Lung Adenocarcinoma Progression by Nkx2-1 |
title_short | Suppression of Lung Adenocarcinoma Progression by Nkx2-1 |
title_sort | suppression of lung adenocarcinoma progression by nkx2-1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088778/ https://www.ncbi.nlm.nih.gov/pubmed/21471965 http://dx.doi.org/10.1038/nature09881 |
work_keys_str_mv | AT winslowmontem suppressionoflungadenocarcinomaprogressionbynkx21 AT daytontalyal suppressionoflungadenocarcinomaprogressionbynkx21 AT verhaakroelgw suppressionoflungadenocarcinomaprogressionbynkx21 AT kimkiselakcaroline suppressionoflungadenocarcinomaprogressionbynkx21 AT snyderericl suppressionoflungadenocarcinomaprogressionbynkx21 AT feldserdavidm suppressionoflungadenocarcinomaprogressionbynkx21 AT hubbarddianad suppressionoflungadenocarcinomaprogressionbynkx21 AT dupagemichelj suppressionoflungadenocarcinomaprogressionbynkx21 AT whittakercharlesa suppressionoflungadenocarcinomaprogressionbynkx21 AT hoerschsebastian suppressionoflungadenocarcinomaprogressionbynkx21 AT yoonstephanie suppressionoflungadenocarcinomaprogressionbynkx21 AT crowleydenise suppressionoflungadenocarcinomaprogressionbynkx21 AT bronsonroderickt suppressionoflungadenocarcinomaprogressionbynkx21 AT chiangdereky suppressionoflungadenocarcinomaprogressionbynkx21 AT meyersonmatthew suppressionoflungadenocarcinomaprogressionbynkx21 AT jackstyler suppressionoflungadenocarcinomaprogressionbynkx21 |